Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OncoZenge ABFRA:8LY -2.28%15 Receivables Turnover is 0.00 as of Jun. 2026. GuruFocus rates FRA:8LY with a GF Score™ of 15/100. The stock has 4 warning signs investors should review. Among 852 Biotechnology companies, OncoZenge AB ranks worse than 84.51% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. OncoZenge AB's Revenue for the
three
months ended in Jun. 2026 was €0.53 Mil. OncoZenge AB's average Accounts Receivable for the
three
months ended in Jun. 2026 was €0.00 Mil.
OncoZenge AB (FRA:8LY) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
OncoZenge AB Receivables Turnover Related Terms
OncoZenge AB Receivables Turnover Historical Data
* Premium members only.
The historical data trend for OncoZenge AB's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8LY vs VRTX, REGN, MRNA: Receivables Turnover Comparison
For the Biotechnology subindustry, OncoZenge AB's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoZenge AB Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OncoZenge AB's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where OncoZenge AB's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoZenge AB (FRA:8LY) has a Receivables Turnover of 0.00 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on OncoZenge AB and its competitors. According to the industry distribution chart, OncoZenge AB ranks #720 out of 852 companies in the Biotechnology industry, placing it in the top 84.5%.
Is OncoZenge AB's Receivables Turnover too high?
OncoZenge AB's current Receivables Turnover is 0.00. Based on the distribution chart, OncoZenge AB ranks #720 out of 852 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, OncoZenge AB has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does OncoZenge AB's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OncoZenge AB ranks #720 out of 852 companies for Receivables Turnover. This places OncoZenge AB in the lower half of its industry. The industry median Receivables Turnover is 5.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on OncoZenge AB and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OncoZenge AB's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoZenge AB stock overvalued right now?
OncoZenge AB (FRA:8LY) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. OncoZenge AB's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For OncoZenge AB (FRA:8LY), the current Receivables Turnover is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.
15GF Score
Get the complete analysis for FRA:8LY
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8LY has been successfully added to your 
